Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 15/20 | 0.39 |
| ▸ | CA2 | P00918 | 15/20 | 0.39 |
| ▸ | CA4 | P22748 | 15/20 | 0.39 |
| ▸ | CA7 | P43166 | 15/20 | 0.39 |
| ▸ | CA9 | Q16790 | 15/20 | 0.39 |
| ▸ | CA1 | P00915 | 14/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22686152 | 0.76 | CA2 (0.32) | CA2CA9 | |
| SCHEMBL22686136 | 0.70 | MB (0.42) | — | |
| SCHEMBL21053191 | 0.67 | PDE3B (0.42) | — | |
| SCHEMBL21054277 | 0.67 | — | — | |
| SCHEMBL22686127 | 0.66 | MARK3 (0.37) | — | |
| SCHEMBL9322559 | 0.65 | ACHE (0.42) | — | |
| SCHEMBL21054112 | 0.65 | CYP11B1 (0.33) | — | |
| SCHEMBL21054030 | 0.64 | CYP11B1 (0.33) | — | |
| SCHEMBL22686147 | 0.64 | NR3C2 (0.36) | — | |
| SCHEMBL22686144 | 0.64 | PDE3B (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | CA12 4810/4885CA2 4638/4885CA4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.